Results 151 to 160 of about 1,519,165 (389)

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Is the Duty to Prevent Genocide an Obligation of Result or an Obligation of Conduct according to the ICJ? (blogpost) [PDF]

open access: yes, 2019
This post analyses the duty to prevent genocide embodied in the 1948 UN Genocide Convention as described by the International Court of Justice in the Bosnia v. Serbia case.
Longobardo, M., Longobardo, M.
core  

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

Carbon tax price reduction obligation [PDF]

open access: yes
Provides information to businesses on the carbon tax price reduction obligation and explains the consequences of a failure to comply. Introduction On 17 July 2014 the Clean Energy Legislation (Carbon Tax Repeal) Act 2014 amended the Competition and ...

core  

Conditions and Causes for Obligation to Mitigate Damages and the Effect of Negligence in It under Iranian and German Law [PDF]

open access: yesپژوهش های حقوق تطبیقی
In case of breaching the contract, the injured party is entitled to receiving the compensation that places him in a status similar to full performance situation. However, if the injured party has a role to increasing the damage, either by failing to take
Mozhdeh Jamsahar   +2 more
doaj  

Home - About - Disclaimer - Privacy